Sandra Ortiz-Cuaran, Translational Research Scientist at Cancer Research Center of Lyon, shared a post on LinkedIn:
“Phase I results of mosperafenib, a novel paradox breaker BRAF inhibitor.
– n=80; 60% prior BRAFi: 63 CRC, 13 melanoma.
– G3–4 TRAEs in 16.3% of patients.
– ORR: 24.2% (2 CRs, 14 PRs).
– mPFS: 6.4 mo in CRC and 3.5 mo in melanoma.”
Title: Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600-Mutant Solid Tumors
Authors: Maria Vieito, Elisa Fontana, Catherine H. Han, Eduardo Castanon, David J. Pinato, Oliver Bechter, Rikke L. Eefsen, Irene Moreno, Hans Prenen, Reinhard Dummer, Ruth Plummer, Gabriel Schnetzler, Martin Kornacker, Piergiorgio Pettazzoni, Florian Renner, Mahdi About, Martha L. Serrano-Serrano, Christina Godfried Sie, Abiraj Keelara, Andreas Roller, David Dejardin, Elisa Cinato, Tomi Fakolade, Ernesto Guarin, Nick Flinn, Nicole A. Kratochwil, Nino Keshelava
Read The Full Article
Other articles about Melanoma on OncoDaily.